A clinical trial testing TG Therapeutics‘ CD20 inhibitor Briumvi (ublituximab-xiiy) in children with relapsing forms of multiple sclerosis (MS) will begin enrolling participants within the next few months, the developer announced, also unveiling details of the study’s design. The upcoming Phase 2/3 trial (NCT07220252) will run in two parallel parts. A Phase 2 portion called […]
The post ACTRIMS 2026: ULTIMATE trial testing Briumvi in kids with MS to launch soon appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com